Search Result

Isoforms Recommended:	SGLT2

Results for "

hSGLT2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) Apoptosis (3) Bacterial (3) Caspase (3) DNA/RNA Synthesis (3) GLUT (3) Isotope-Labeled Compounds (2) JAK (3) mTOR (3) NF-κB (3) PI3K (3) Reference Standards (3) SGLT (20) STAT (3)
By Research Areas:	Cancer (6) Infection (3) Metabolic Disease (18) Neurological Disease (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10451

Canagliflozin Maximum Cited Publications 46 Publications Verification JNJ 28431754	SGLT	Metabolic Disease Cancer
Canagliflozin (JNJ 28431754) is a selective *SGLT2* inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .

HY-N0143

Phlorizin 10+ Cited Publications Floridzin	Caspase JAK GLUT STAT Apoptosis Bacterial SGLT mTOR Akt NF-κB PI3K DNA/RNA Synthesis	Infection Neurological Disease Metabolic Disease Cancer
Phlorizin (Floridzin) is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC₅₀ of 0.04 μM and a K_i of 39 nM against *hSGLT2, and an IC₅₀* of 0.17 μM and a K_i of 0.31 μM against *hSGLT1. Phlorizin promotes GLUT4* translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities ^[2] .

HY-15461

Ertugliflozin 5 Publications Verification PF-04971729	SGLT	Metabolic Disease
Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus ^[2].

HY-I0383

Canagliflozin hemihydrate Maximum Cited Publications 46 Publications Verification JNJ 28431754 hemihydrate	SGLT	Metabolic Disease Cancer
Canagliflozin hemihydrate (JNJ28431754 hemihydrate) is a selective *SGLT2* inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .

HY-15461A

Ertugliflozin L-pyroglutamic acid 5 Publications Verification PF-04971729 L-pyroglutamic acid	SGLT	Metabolic Disease
Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus ^[2].

HY-14945

Remogliflozin etabonate GSK189075	SGLT	Metabolic Disease
Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with K_i values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .

HY-N0143A

Phlorizin dihydrate 10+ Cited Publications Floridzin dihydrate	SGLT PI3K Akt GLUT NF-κB JAK STAT Caspase Apoptosis DNA/RNA Synthesis mTOR Bacterial	Infection Neurological Disease Metabolic Disease Cancer
Phlorizin (Floridzin) dihydrate is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC₅₀ of 0.04 μM and a K_i of 39 nM against *hSGLT2, and an IC₅₀* of 0.17 μM and a K_i of 0.31 μM against *hSGLT1. Phlorizin dihydrate promotes GLUT4* translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin dihydrate reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin dihydrate induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin dihydrate also exhibits antibacterial, anti-inflammatory and neuroprotective activities ^[2] .

HY-15461R

Ertugliflozin (Standard) PF-04971729 (Standard)	Reference Standards SGLT	Metabolic Disease
Ertugliflozin (Standard) is the analytical standard of Ertugliflozin. This product is intended for research and analytical applications. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus ^[2].

HY-14810

Atigliflozin AVE-2268	SGLT	Metabolic Disease
Atigliflozin (AVE-2268) is an orally active and selective *SGLT-2* inhibitor, with IC₅₀s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .

HY-137145

galacto-Dapagliflozin	SGLT	Others
Galacto-dapagliflozin is a selective inhibitor for *hSGLT2* with K_i of 25 nM .

HY-114308

SGL5213	SGLT	Metabolic Disease
SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC₅₀ values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment .

HY-10451R

Canagliflozin (Standard) JNJ 28431754 (Standard)	Reference Standards SGLT	Metabolic Disease Cancer
Canagliflozin (Standard) is the analytical standard of Canagliflozin. This product is intended for research and analytical applications. Canagliflozin (JNJ 28431754) is a selective *SGLT2* inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .

HY-124664

TP0438836	SGLT	Metabolic Disease
TP0438836 (compound 30b) is a *SGLT1* inhibitor, with IC₅₀ values of 28 nM and 7 nM for hSGLT1 and hSGLT2, respectively. TP0438836 can be used in diabetes research .

HY-112807

SGLT inhibitor-1	SGLT	Metabolic Disease
SGLT inhibitor-1 is a potent dual inhibitor of sodium glucose co-transporter proteins (SGLTs), inhibits hSGLT1 and hSGLT2 with IC₅₀s of 43 nM and 9 nM, respectively .

HY-165438

Sergliflozin-A	SGLT	Others
Sergliflozin-A is a compound used to inhibit type 2 diabetes. It can inhibit glucose transporters in the kidney, competitively inhibit hSGLT1 and hSGLT2, and mutations at different sites have different effects on its inhibitory effect.

HY-10451S2

Canagliflozin-d6 JNJ 28431754-d₆	SGLT	Metabolic Disease
Canagliflozin-d₆ is the deuterium labeled Canagliflozin . Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively ^[2].

HY-15461S

Ertugliflozin-d5 PF-04971729-d₅	SGLT	Metabolic Disease
Ertugliflozin-d₅ is the deuterium labeled Ertugliflozin . Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 ^[2]. Has the potential for the treatment of type 2 diabetes mellitus .

HY-15461S1

Ertugliflozin-d9 PF-04971729-d₉	SGLT Isotope-Labeled Compounds	Metabolic Disease
Ertugliflozin-d₉ is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus ^[2].

HY-N0143R

Phlorizin (Standard) Floridzin (Standard)	Reference Standards Caspase JAK GLUT STAT Apoptosis Bacterial SGLT mTOR Akt NF-κB PI3K DNA/RNA Synthesis	Infection Neurological Disease Metabolic Disease Cancer
Phlorizin (Floridzin) (Standard) is the analytical standard of Phlorizin. This product is intended for research and analytical applications. Phlorizin is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC₅₀ of 0.04 μM and a K_i of 39 nM against *hSGLT2, and an IC₅₀* of 0.17 μM and a K_i of 0.31 μM against *hSGLT1. Phlorizin promotes GLUT4* translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities ^[2] .

HY-166548S

Remogliflozin etabonate-d7 GSK189075-d₇	Isotope-Labeled Compounds SGLT	Others Metabolic Disease
Remogliflozin etabonate-d₇ (GSK189075-d₇) is the deuterium labeled Remogliflozin etabonate. Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with K_i values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .

Cat. No.	Product Name	Type

HY-N0143A

Phlorizin dihydrate 10+ Cited Publications Floridzin dihydrate	Biochemical Assay Reagents
Phlorizin (Floridzin) dihydrate is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC₅₀ of 0.04 μM and a K_i of 39 nM against *hSGLT2, and an IC₅₀* of 0.17 μM and a K_i of 0.31 μM against *hSGLT1. Phlorizin dihydrate promotes GLUT4* translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin dihydrate reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin dihydrate induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin dihydrate also exhibits antibacterial, anti-inflammatory and neuroprotective activities ^[2] .

Phlorizin dihydrate

10+ Cited Publications

Floridzin dihydrate

Biochemical Assay Reagents

Phlorizin (Floridzin) dihydrate is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC₅₀ of 0.04 μM and a K_i of 39 nM against hSGLT2, and an IC₅₀ of 0.17 μM and a K_i of 0.31 μM against hSGLT1. Phlorizin dihydrate promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin dihydrate reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin dihydrate induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin dihydrate also exhibits antibacterial, anti-inflammatory and neuroprotective activities ^[2] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0143

Phlorizin 10+ Cited Publications Floridzin	Structural Classification Flavonoids Classification of Application Fields Malus pumila Mill. Rosaceae Phenols Polyphenols Metabolic Disease Plants Dihydrochalcones Disease Research Fields Source Classification	Caspase JAK GLUT STAT Apoptosis Bacterial SGLT mTOR Akt NF-κB PI3K DNA/RNA Synthesis
Phlorizin (Floridzin) is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC₅₀ of 0.04 μM and a K_i of 39 nM against *hSGLT2, and an IC₅₀* of 0.17 μM and a K_i of 0.31 μM against *hSGLT1. Phlorizin promotes GLUT4* translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities ^[2] .

HY-N0143R

Phlorizin (Standard) Floridzin (Standard)	Structural Classification Flavonoids Malus pumila Mill. Rosaceae Phenols Polyphenols Plants Dihydrochalcones Source Classification	Reference Standards Caspase JAK GLUT STAT Apoptosis Bacterial SGLT mTOR Akt NF-κB PI3K DNA/RNA Synthesis
Phlorizin (Floridzin) (Standard) is the analytical standard of Phlorizin. This product is intended for research and analytical applications. Phlorizin is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC₅₀ of 0.04 μM and a K_i of 39 nM against *hSGLT2, and an IC₅₀* of 0.17 μM and a K_i of 0.31 μM against *hSGLT1. Phlorizin promotes GLUT4* translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities ^[2] .

Cat. No.	Product Name	Chemical Structure

HY-10451S2

Canagliflozin-d6
Canagliflozin-d₆ is the deuterium labeled Canagliflozin . Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively ^[2].

HY-15461S

Ertugliflozin-d5
Ertugliflozin-d₅ is the deuterium labeled Ertugliflozin . Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 ^[2]. Has the potential for the treatment of type 2 diabetes mellitus .

HY-15461S1

Ertugliflozin-d9
Ertugliflozin-d₉ is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus ^[2].

HY-166548S

Remogliflozin etabonate-d7
Remogliflozin etabonate-d₇ (GSK189075-d₇) is the deuterium labeled Remogliflozin etabonate. Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with K_i values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .

Remogliflozin etabonate-d7

Remogliflozin etabonate-d₇ (GSK189075-d₇) is the deuterium labeled Remogliflozin etabonate. Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with K_i values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

hSGLT2

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Natural
Products